<DOC>
	<DOCNO>NCT00733187</DOCNO>
	<brief_summary>To estimate effect food oral bioavailability effect diurnal variation pharmacokinetics ABT-869 .</brief_summary>
	<brief_title>Pharmacokinetic Study To Evaluate Effect Food Diurnal Variation ABT-869</brief_title>
	<detailed_description>This study pharmacokinetic study design evaluate effect food oral bioavailability effect diurnal variation pharmacokinetics ABT-869 . Triplicate ECG perform determine effect ABT-869 QT prolongation . Subjects may continue receive linifanib completion study .</detailed_description>
	<criteria>Male female age ≥ 18 year . Must histologically cytologically confirm nonhematologic malignancy refractory standard therapy standard effective therapy exist . Has measurable evaluable disease . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . Must adequate bone marrow , renal hepatic function follow : Bone Marrow : Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ ; Platelets ≥ 100,000/mm³ ; Hemoglobin ≥ 9.0 g/dL ( 1.4 mmol/L ) Renal function : serum creatinine ≤ 2.0 mg/dL ( 0.81 mmol/L ) ; Hepatic function : AST ALT ≤ 1.5 × ULN unless liver metastasis present , AST ALT ≤ 5.0 × ULN ; bilirubin ≤ 1.5 mg/dL ( 0.026 mmol/L ) Must PTT ≤ 1.5 × ULN and/or INR ≤ 1.5 . Women childbearing potential men must agree use adequate contraception ( one follow list ) prior study entry , duration study participation two month follow completion therapy . Women childbearing potential must negative urine pregnancy test within 7 day prior initiation treatment and/or post menopausal woman must amenorrheic least 12 month consider nonchildbearing potential . total abstinence sexual intercourse ( minimum one complete menstrual cycle ) ; vasectomize partner ; hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; intrauterine device ; * doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) Is capable understand comply parameter outline protocol able sign inform consent . Must voluntarily sign date inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . Has receive anticancer therapy within 21 day within period define 5 half life , whichever short , prior study drug administration . Has recover less equal Grade 1 clinically significant adverse effects/toxicities previous therapy . Avastin must use less 60 day prior receive ABT869 . Has major surgery within 21 day Study Day 1 . Has untreated brain meningeal metastasis . Subjects treat , stable , asymptomatic central nervous system lesion may consider . Subject must stable disease least 4 week prior study entry . Has diagnose hepatocellular carcinoma . Pregnant breastfeed female . Is receive therapeutic anticoagulation therapy . Low dose anticoagulation catheter prophylaxis permit . Has history of/or currently exhibit clinically significant cancer relate event bleed . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant sign bleed . Has proteinuria CTC Grade &gt; 1 baseline measure UPC ratio &gt; 1 confirm 24 hour urine collection . . Currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure ( BP ) &gt; 100 mmHg ; systolic blood pressure ( BP ) &gt; 150 mmHg . Has history myocardial infarction within 6 month Study Day 1 . Has know autoimmune disease renal involvement . Is receive combination antiretroviral therapy human immunodeficiency virus ( HIV ) . Clinically significant uncontrolled condition ( ) . Has active ulcerative colitis , Crohn 's disease celiac disease . LV Ejection Fraction &lt; 50 % . Current previous enrollment another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>